|
I.A. Baranova
DIAGNOSIS AND TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS
|
12-18 |
|
D.V. Akimova
RISK FACTORS FOR OSTEOPOROSIS
|
19-24 |
|
E.G. Zotkin
SOME FEATURES OF TREATMENT OF INVOLUTIONAL OSTEOPOROSIS USING BISPHOSPHONATES IN ELDERLY PATIENTS
|
25-30 |
|
M.V.Zamergrad (1, 2)
PHARMACOTHERAPY OF VESTIBULAR VERTIGO
|
31-34 |
|
R.Ts.Bembeeva (1), K.I.Kirgizov (2, 3), E.I.Skorobogatova (2), E.Yu.Volkova (2)
APPROACHES TO THE THERAPY OF REFRACTORY MULTIPLE SCLEROSIS IN CHILDREN
|
35-39 |
|
E.A. Aseeva, M.E. Tsanyan, A.V. Torgashina
PROSPECTS FOR ANTI-B-CELL THERAPY OF SYSTEMIC LUPUS ERYTHEMATOSUS
|
40-44 |
|
N.V. Seredavkina, T.M. Reshetnyak, E.L. Nasonov
INTRAVENOUS HUMAN IMMUNOGLOBULIN IN RHEUMATOLOGY
|
45-53 |
|
O.V. Kotova , E.S. Akarachkova
LOCAL ANALGETIC THERAPY
|
54-56 |
|
A.V. Belopasova, A.S. Kadykov
ASTHENIC CONDITIONS IN PATIENTS WITH CEREBROVASCULAR DISEASES. POTENTIALS FOR THEIR CORRECTION
|
57-61 |
|
I.S. Dydykina, P.S. Dydykina
COMPREHENSIVE APPROACH TO TREATMENT OF PAIN IN OSTEOARTHROSIS USING XEFOCAM ( LORNOXICAM )
|
62-67 |
|
V.V. Ryazhenov (1), S.G. Gorokhova (2), I.V. Emchenko (3)
CLINICAL AND ECONOMIC ASSESSMENT OF DIFFERENT STRATEGIES FOR TREATMENT OF PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
|
68-76 |
|
I.Yu. Zinchuk
PHARMACOECONOMIC ANALYSIS OF GENETICALLY ENGINEERED BIOLOGICAL PRODUCTS USED IN THE TREATMENT OF PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS
|
77-82 |
|
M.V. Putilina
POTENTIALS FOR THE PREVENTIVE THERAPY OF NEUROLOGICAL MANIFESTATIONS OF CHRONIC CEREBRAL ISCHEMIA IN THERAPEUTICAL PRACTICE
|
83-90 |
|
O.A. Shavlovskaya
Diabetic polyneuropathy: efficacy of therapy with actovegin
|
91-93 |
|
V.B. Laskov, I.V. Laskova
ASTHENOVEGETATIVE DYSFUNCTION: CLINICAL MANIFESTATIONS AND METHODS FOR ITS CORRECTION IN SCHOOL-AGED CHILDREN
|
94-97 |
|
Yu.B. Belousov (1), M.V. Leonova (1), L.L. Shteinberg (1), I.F. Tischenkova (1), A.V. Sokolov (2)
APPLICATION OF ANTICONVULSANTS FROM THE POSITION OF CONCENTRATION MONITORING: CURRENT DATA
|
98-103 |
Русский
